Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes

被引:22
|
作者
Home, P. D. [1 ]
Meneghini, L. [2 ]
Wendisch, U.
Ratner, R. E. [3 ]
Johansen, T. [4 ]
Christensen, T. E. [4 ]
Jendle, J. [5 ]
Roberts, A. P. [6 ]
Birkeland, K. I. [7 ]
机构
[1] Newcastle Univ, Sch Med, ICM Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[3] MedStar Hlth Res Inst, Hyattsville, MD USA
[4] Novo Nordisk AS, Soborg, Denmark
[5] Univ Orebro, Endocrine & Diabet Ctr, Karlstad Hosp, Fac Hlth Sci, Orebro, Sweden
[6] Royal Adelaide Hosp, Endocrine & Metab Unit, Adelaide, SA 5000, Australia
[7] Univ Oslo, Fac Med, Dept Endocrinol, Oslo Univ Hosp, Oslo, Norway
关键词
hypoglycaemia; insulin; insulin therapy; quality of life; Type; 1; diabetes; HYPOGLYCEMIA; METFORMIN;
D O I
10.1111/j.1464-5491.2011.03547.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabet. Med. 29, 716720 (2012) Abstract Aims The efficacy and safety of insulin degludec (degludec), a new-generation ultra-long-acting basal insulin, was compared with insulin glargine (glargine) in people with Type 1 diabetes mellitus in a 16-week, open-label, randomized trial. Health status, an important aspect of effective diabetes management, was also assessed. Methods Degludec (n = 59) or glargine (n = 59) were injected once daily, with insulin aspart at mealtimes. Health status assessment utilized the validated Short Form 36 Health Survey, version 2, which has two summary component scores for mental and physical well-being, each comprising four domains. Results At study end, HbA1c reductions were comparable between groups, but confirmed nocturnal hypoglycaemia was significantly less frequent with degludec [relative rate 0.42 (95% CI 0.250.69)], and overall hypoglycaemia numerically less frequent [relative rate 0.72 (95% CI 0.521.00)]. After 16 weeks, a significant improvement in Short Form 36 Health Survey mental component score of +3.01 (95% CI 0.325.70) was obtained for degludec against glargine, attributable to significant differences in the social functioning [+8.04 (95% CI 1.8914.18)] and mental health domains [+2.46 (95% CI 0.104.82)]. For mental component score, Cohens effect size was 0.42, indicating a small-to-medium clinically meaningful difference. The physical component score [+0.66 (95% CI 2.30 to 3.62)] and remaining domains were not significantly different between degludec and glargine. Conclusions In the context of comparable overall glycaemic control with glargine, degludec improved mental well-being as measured using the mental component score of the Short Form 36 Health Survey. The improvements in overall mental component score and the underlying social functioning and mental health domains with degludec compared with glargine may relate to the observed reduction in hypoglycaemic events.
引用
收藏
页码:716 / 720
页数:5
相关论文
共 50 条
  • [1] Health status in people with type 2 diabetes on basal-oral therapy is significantly improved with insulin degludec vs insulin glargine
    Jendle, J.
    Freemantle, N.
    Meneghini, L.
    Christensen, T. E.
    Wolden, M. L.
    Ratner, R. E.
    [J]. DIABETOLOGIA, 2012, 55 : S393 - S393
  • [2] Health Status in People With Type 2 Diabetes on Basal-Oral Therapy is Significantly Improved With Insulin Degludec vs. Insulin Glargine
    Freemantle, Nick
    Meneghini, Luigi
    Christensen, Torsten E.
    Wolden, Michael
    Jendle, Johan
    Ratner, Robert E.
    [J]. DIABETES, 2012, 61 : A313 - A313
  • [3] Comparison of Insulin Glargine with Insulin Degludec in Type 1 Diabetes Patients
    Kuroda, Akio
    Tsuruo, Miho
    Takeshi, Kondo
    Aki, Nanako
    Oguro, Yukari
    Endo, Itsuro
    Aihara, Ken-ichi
    Tamaki, Motoyuki
    Matsumoto, Toshio
    Matsuhisa, Munehide
    [J]. DIABETES, 2014, 63 : A232 - A232
  • [4] Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes
    Urakami, Tatsuhiko
    Kuwabara, Remi
    Aoki, Masako
    Okuno, Misako
    Suzuki, Junichi
    [J]. ENDOCRINE JOURNAL, 2016, 63 (02) : 159 - 167
  • [5] A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes
    Home, PD
    Rosskamp, R
    Forjanic-Klapproth, J
    Dressler, A
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2005, 21 (06) : 545 - 553
  • [6] Insulin Degludec Reduces Hypoglycemia and Improves Health Status vs. Insulin Glargine in Insulin-Naive Type 2 Diabetes
    Rodbard, Helena W.
    Handelsman, Yehuda
    Cariou, Bertrand
    Johansen, Thue
    Christensen, Torsten E.
    Mathieu, Chantal
    [J]. DIABETES, 2012, 61 : A307 - A308
  • [7] A comparison of quality of life measured with the SF-36 for insulin degludec and insulin glargine in people with type 1 diabetes
    Home, P. D.
    Meneghini, L.
    Ratner, R. E.
    Johansen, T.
    Christensen, T. E.
    Jendle, J.
    Roberts, A. P.
    DeVries, J. H.
    Birkeland, K. I.
    [J]. DIABETOLOGIA, 2011, 54 : S384 - S384
  • [8] A two year randomised trial: improved glycaemic control and lower risk of nocturnal hypoglycaemia with insulin degludec compared with insulin glargine in Type 1 diabetes
    Russell-Jones, D. L.
    Heller, S.
    Hansen, C. T.
    Chang, D.
    Bode, B.
    [J]. DIABETIC MEDICINE, 2013, 30 : 74 - 74
  • [9] Type 2 Diabetes: Direct Comparison between Insulin Glargine and Insulin Degludec
    Lichert, Frank
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2018, 13 (06) : 546 - 546
  • [10] Insulin degludec is associated with less frequent and milder hypoglycemia in insulin-deficient patients with type 1 diabetes compared with insulin glargine or detemir
    Iwasaki S.
    Kozawa J.
    Kimura T.
    Fukui K.
    Iwahashi H.
    Imagawa A.
    Shimomura I.
    [J]. Diabetology International, 2017, 8 (2) : 228 - 236